medigraphic.com
Colegio de Medicina Interna de México.

2024, Number 3

<< Back Next >>

Med Int Mex 2024; 40 (3)

Fungal meningitis: preliminary results of the medical care protocol in a second level hospital

Maldonado MJA, Medrano OJJ, Juárez DR, Durán AR, González PR, Alfaro CJA

Language: Spanish
References: 37
Page: 191-200
PDF size: 231.91 Kb.


ABSTRACT

Objective: To analyze the patients who underwent surgery in two private clinics, from January 2023 to date, in Matamoros, Tamaulipas, Mexico, and to establish the possibility of having contracted fungal meningitis.
Materials and Methods: Observational, descriptive study using statistical analysis technique, including all patients who met any of the three predictions established of the entering protocol with a probability of fungal meningitis. A clinical record was kept for all cases and a database was created at the time of admission including: age, sex, age group, clinical data, characterization of fungal meningitis, type of surgery, date of surgery and type of anaesthesia.
Results: Of 405 patients identified, 50 were from Matamoros, Tamaulipas, and all of them were asked to undergo their medical check-up at the general hospital of this town; only 26 attended: 24 were female and 2 were male. Of them, 4/26 were PCR positive for Fusarium solani, with cosmetic surgery and epidural anesthesia being predominant factors. The clinical picture appeared within a period of 30 to 60 days, stiff neck was the main symptom in 3/26 patients. Tomography scans were reported to have no morphological alterations upon admission.
Conclusions: In fungal infection of the central nervous system the cabinet images are very non-specific; thus the faster and more reliable diagnostic method is PCR in cerebrospinal fluid. The inoculation of the fungus with contaminated drugs, in healthy patients, is perhaps the most accepted cause in this research.


REFERENCES

  1. Hoenigl M, Salmanton-García J, Walsh TJ, Nucci M, et al.Global guideline for the diagnosis and management of raremould infections: an initiative of the European Confederationof Medical Mycology in cooperation with the InternationalSociety for Human and Animal Mycology and theAmerican Society for Microbiology. Lancet Infect Dis 2021;21 (8): e246-e257. doi: 10.1016/S1473-3099(20)30784-2.

  2. Alavi Darazam I, Sharifi G, Jamali E, Khodavaisy S, et al.Meningoencephalitis caused by Fusarium proliferatum:an unusual case. Infection 2022; 50: 1023-1027. https://doi.org/10.1007/s15010-022-01761-7.

  3. Hof H. The medical relevance of Fusarium spp. J Fungi 2020;6 (3): 117. https://doi.org/10.3390/jof6030117.

  4. Peterson A, Pham MH, Lee B, Commins D, Cadden J, GiannottaSL, Zada G. Intracranial Fusarium fungal abscess in animmunocompetent patient: case report and review of theliterature. J Neurol Surg Rep 2014; 75: e241-e245. https://doi. org/10.1055/s-0034-1387182.

  5. Garcia RR, Min Z, Narasimhan S, Bhanot N. Fusarium brainabscess: case report and literature review. Mycoses 2015;58: 22-6. https://doi.org/10.1111/myc.12271.

  6. Nucci M, Marr KA, Queiroz-Telles F, Martins C, et al. Fusariuminfection in hematopoietic stem cell transplantrecipients. Clin Infect Dis 2004; 38: 1237-42.

  7. Nielsen SE, Nielsen E, Julian HO, Lindegaard J, et al. Incidenceand clinical characteristics of fungal keratitis in aDanish population from 2000 to 2013. Acta Ophthalmol2015; 93: 54-58. doi: 10.1111/aos.12440.

  8. Schwartz S, Kontoyiannis DP, Harrison T, Ruhnke M. Avancesen el diagnóstico y tratamiento de infecciones fúngicas delSNC. Lancet Neurol 2018; 17 (4): 362-72.

  9. Organización Panamericana de la Salud. Nota Técnica:Meningitis de origen desconocido México. https://www.paho.org/es/documentos/nota-tecnica-meningitis-origendesconocido-mexico.

  10. Dananché C, Cassier P, Sautour M, Gautheron N, Wegrzyn J,Perraud M, Bienvenu AL, Nicolle MC, Boibieux A, VanhemsP. Fungaemia caused by Fusarium proliferatum in a patientwithout definite immunodeficiency. Mycopathologia 2015;179 (1-2): 135-40. doi: 10.1007/s11046-014-9817-6.

  11. Hoenigl M, Jenks JD, Egger M, Nucci M, Thompson GR 3rd.Treatment of Fusarium Infection of the central nervoussystem: A review of past cases to guide therapy for theongoing 2023 outbreak in the United States and Mexico.Mycopathologia 2023. doi: 10.1007/s11046-023-00790-6.

  12. Bassetti M, Azoulay E, Kullberg BJ, Ruhnke M, Shoham S,Vazquez J, Giacobbe DR, Calandra T. EORTC/MSGERC definitionsof invasive fungal diseases: summary of activitiesof the Intensive Care Unit Working Group. Clin Infect Dis2021; 72 (Suppl 2): S121-S127. doi: 10.1093/cid/ciaa1751.

  13. Brumble LM, Reza MB, Dhakal LP, Cruz G, Abu SalehOM, Heckman MG, et al. Fungal infections of the centralnervous system: clinical, radiographic and laboratory manifestations.J Microbiol Exp 2017; 5: 00167. https://doi.org/10.15406/ jmen.2017.05.00167.

  14. Gavito-Higuera J, Mullins CB, Ramos-Duran L, Olivas ChaconCI, Hakim N, Palacios E. Fungal infections of the centralnervous system: a pictorial review. J Clin Imaging Sci 2016;6: 24. https://doi.org/10.4103/2156-7514.184244.

  15. Murthy JMK, Sundaram C. Fungal infections of thecentral nervous system. In. Biller J, Ferro JM, editors.Handbook of clinical neurology. Elsevier, New York:2014; 1383–401.

  16. Liu Y, Mittal R, Solis NV, Prasadarao NV, Filler SG. Mechanismsof Candida albicans trafficking to the brain. PLoSPathog 2011; 7: e1002305. https://doi.org/10.1371/journal.ppat.1002305.

  17. Candoni A, Klimko N, Busca A, Di Blasi R, et al. Fungalinfections of the central nervous system and paranasalsinuses in onco-haematologic patients. Epidemiologicalstudy reporting the diagnostic-therapeutic approach andoutcome in 89 cases. Mycoses 2019; 62 (3): 252-260. doi:10.1111/myc.12884.

  18. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, MylonakisaE. Molecular and nonmolecular diagnostic methodsfor invasive fungal infections. Clin Microbiol Rev 2014; 27:490-526. https://doi.org/10.1128/CMR.00091-13.

  19. Gavito-Higuera J, Mullins CB, Ramos-Duran L, Olivas ChaconCI, Hakim N, Palacios E. Fungal infections of the centralnervous system: a pictorial review. J Clin Imaging Sci 2016;6: 24. https://doi.org/10.4103/2156-7514.184244.

  20. Chong GM, Maertens JA, Lagrou K, Driessen GJ, CornelissenJJ, Rijnders BJ. Diagnostic performance of galactomannanantigen testing in cerebrospinal fluid. J Clin Microbiol 2016;54: 428-31. https://doi.org/10.1128/JCM.02913-15.

  21. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP,Walsh TJ. Mold Infections of the central nervous system.N Engl J Med 2014; 371: 150-60. https://doi.org/10.1056/NEJMr a1216008.

  22. Kozel TR, Wickes B. Fungal diagnostics. Cold Spring HarbPerspect Med 2014; 4: a019299. https://doi.org/10.1101/cshperspec t.a019299.

  23. Calderaro A, Martinelli M, Motta F, Larini S, ArcangelettiMC, Medici MC, et al. Comparison of peptide nucleic acidfluorescence in situ hybridization assays with culturebasedmatrix assisted laser desorption/ionization-time offlight mass spectrometry for the identification of bacteriaand yeasts from blood cultures and cerebrospinal fluidcultures. Clin Microbiol Infect 2014; 20: 468-75. https://doi.org/10.1111/1469-0691.12490.

  24. Reinwald M, Buchheidt D, Hummel M, Duerken M, BertzH, Schwerdtfeger R, et al. Diagnostic performance of anAspergillus-specific nested PCR assay in cerebrospinalfluid samples of immunocompromised patients fordetection of central nervous system aspergillosis. PlosOne 2013; 8: e56706. https://doi. org/10.1371/journal.pone.0056706.

  25. Buitrago MJ, Gomez-Lopez A, Mellado E, Rodriguez-TudelaJL, Cuenca-Estrella M. Detection of Aspergillus spp. realtime in a mouse model of lung infection. Enferm InfeccMicrobiol Clin 2005; 23: 464-468.

  26. Góralska K, Blaszkowska J, Dzikowiec, M. Neuroinfectionscaused by fungi. Infection 2018; 46: 443-459. https://doi.org/10.1007/s15010-018-1152-2.

  27. Smith RM, Schaefer MK, Kainer MA, Wise M, et al. Fungalinfections associated with contaminated methylprednisoloneinjections. N Engl J Med 2013; 369: 1598-609. DOI:10.1056/NEJMoa1213978.

  28. Liu Y, Feng M, Yao Y, Deng K, et al. Cryptococcal meningitisafter transnasal transsphenoidal pituitary microsurgeryof ACTH-secreting pituitary adenoma: a case report.Medicine (Baltimore) 2017; 96: e7124. doi: 10.1097/MD.0000000000007124.

  29. Secretaría de Salud de México-Comunicado de prensa:Continúa investigación sobre causas de meningitis en Durango:Hugo López-Gatell Ramírez. Disponible en: https://bit.ly/3ODmIMo.

  30. Raman Sharma R. Fungal infections of the nervous system:current perspective and controversies in management. Int JSurg 2010; 8 (8): 591-601. doi: 10.1016/j.ijsu.2010.07.293.

  31. Bongomin F, Gago S, Oladele RO, Denning DW. Global andmulti-national prevalence of fungal diseases-estimateprecision. J Fungi (Basel) 2017; 3 (4): 57. doi: 10.3390/jof3040057.

  32. Ruhnke M, Cornely OA, Schmidt-Hieber M, Alakel N, BoellB, Buchheidt D, et al. Tratamiento de las enfermedadesfúngicas invasoras en pacientes con cáncer. Revisadas 2019Recomendaciones del Grupo de Trabajo de EnfermedadesInfecciosas (AGIHO) de la Sociedad Alemana de Hematologíay Oncología (DGHO). Mycoses 2020.

  33. Nucci M Anaissie E. Fusarium infections in immunocompromisedpatients. Clin Microbiol Rev 2007; 20 (4): 695-704.doi: 10.1128/CMR.00014-07.

  34. Park BJ, Wannemuehler KA, Marston BJ, Govender N,Pappas PG, Chiller TM. Estimación de la carga mundialactual de la meningitis criptocócica entre las personas queviven con el VIH/SIDA. SIDA 2009; 23: 525-530.

  35. Mathur M, Johnson CE, Sze G. Fungal infections of thecentral nervous system. Neuroimaging Clin N Am 2012;22: 609-32. doi: 10.1016/j.nic.2012.04.004.

  36. Black KE, Baden LR. Fungal infections of the CNS: treatmentstrategies for the immunocompromised patient. CNSDrugs 2007; 21 (4): 293-318. doi: 10.2165/00023210-200721040-00004.

  37. Zarrin M, Zarei Mahmoudabadi A. Infecciones fúngicasdel sistema nervioso; un artículo de revisión. JundishapurJ Microbiol 2010; 3 (2): 41-47.




2020     |     www.medigraphic.com